The Efficacy and Safety of Inetetamab and Pyrotinib in Combination with Vinorelbine for Second-line Therapy and Beyond in HER2-positive Metastatic Breast Cancer: A Single-institution Clinical Experience
CONCLUSION: Inetetamab and pyrotinib in combination with vinorelbine have good efficacy in ≥2ndline treatment of HER2-positive MBC with controllable toxicity, and the combination is a new treatment option, especially for patients who cannot use ADCs in 2nd-line treatment.PMID:37916639 | DOI:10.2174/0115680096248592231016065117 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - November 2, 2023 Category: Cancer & Oncology Authors: Fan Wu Mulan Chen Lili Wang Xiufeng Wu Xinhua Chen Yi Hong Chongyin Li Lin Lin Kan Chen Jian Liu Weiwei Huang Nani Li Source Type: research
The Efficacy and Safety of Inetetamab and Pyrotinib in Combination with Vinorelbine for Second-line Therapy and Beyond in HER2-positive Metastatic Breast Cancer: A Single-institution Clinical Experience
CONCLUSION: Inetetamab and pyrotinib in combination with vinorelbine have good efficacy in ≥2ndline treatment of HER2-positive MBC with controllable toxicity, and the combination is a new treatment option, especially for patients who cannot use ADCs in 2nd-line treatment.PMID:37916639 | DOI:10.2174/0115680096248592231016065117 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - November 2, 2023 Category: Cancer & Oncology Authors: Fan Wu Mulan Chen Lili Wang Xiufeng Wu Xinhua Chen Yi Hong Chongyin Li Lin Lin Kan Chen Jian Liu Weiwei Huang Nani Li Source Type: research
The Efficacy and Safety of Inetetamab and Pyrotinib in Combination with Vinorelbine for Second-line Therapy and Beyond in HER2-positive Metastatic Breast Cancer: A Single-institution Clinical Experience
CONCLUSION: Inetetamab and pyrotinib in combination with vinorelbine have good efficacy in ≥2ndline treatment of HER2-positive MBC with controllable toxicity, and the combination is a new treatment option, especially for patients who cannot use ADCs in 2nd-line treatment.PMID:37916639 | DOI:10.2174/0115680096248592231016065117 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - November 2, 2023 Category: Cancer & Oncology Authors: Fan Wu Mulan Chen Lili Wang Xiufeng Wu Xinhua Chen Yi Hong Chongyin Li Lin Lin Kan Chen Jian Liu Weiwei Huang Nani Li Source Type: research
The Efficacy and Safety of Inetetamab and Pyrotinib in Combination with Vinorelbine for Second-line Therapy and Beyond in HER2-positive Metastatic Breast Cancer: A Single-institution Clinical Experience
CONCLUSION: Inetetamab and pyrotinib in combination with vinorelbine have good efficacy in ≥2ndline treatment of HER2-positive MBC with controllable toxicity, and the combination is a new treatment option, especially for patients who cannot use ADCs in 2nd-line treatment.PMID:37916639 | DOI:10.2174/0115680096248592231016065117 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - November 2, 2023 Category: Cancer & Oncology Authors: Fan Wu Mulan Chen Lili Wang Xiufeng Wu Xinhua Chen Yi Hong Chongyin Li Lin Lin Kan Chen Jian Liu Weiwei Huang Nani Li Source Type: research
The Efficacy and Safety of Inetetamab and Pyrotinib in Combination with Vinorelbine for Second-line Therapy and Beyond in HER2-positive Metastatic Breast Cancer: A Single-institution Clinical Experience
CONCLUSION: Inetetamab and pyrotinib in combination with vinorelbine have good efficacy in ≥2ndline treatment of HER2-positive MBC with controllable toxicity, and the combination is a new treatment option, especially for patients who cannot use ADCs in 2nd-line treatment.PMID:37916639 | DOI:10.2174/0115680096248592231016065117 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - November 2, 2023 Category: Cancer & Oncology Authors: Fan Wu Mulan Chen Lili Wang Xiufeng Wu Xinhua Chen Yi Hong Chongyin Li Lin Lin Kan Chen Jian Liu Weiwei Huang Nani Li Source Type: research
The Efficacy and Safety of Inetetamab and Pyrotinib in Combination with Vinorelbine for Second-line Therapy and Beyond in HER2-positive Metastatic Breast Cancer: A Single-institution Clinical Experience
CONCLUSION: Inetetamab and pyrotinib in combination with vinorelbine have good efficacy in ≥2ndline treatment of HER2-positive MBC with controllable toxicity, and the combination is a new treatment option, especially for patients who cannot use ADCs in 2nd-line treatment.PMID:37916639 | DOI:10.2174/0115680096248592231016065117 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - November 2, 2023 Category: Cancer & Oncology Authors: Fan Wu Mulan Chen Lili Wang Xiufeng Wu Xinhua Chen Yi Hong Chongyin Li Lin Lin Kan Chen Jian Liu Weiwei Huang Nani Li Source Type: research
The Efficacy and Safety of Inetetamab and Pyrotinib in Combination with Vinorelbine for Second-line Therapy and Beyond in HER2-positive Metastatic Breast Cancer: A Single-institution Clinical Experience
CONCLUSION: Inetetamab and pyrotinib in combination with vinorelbine have good efficacy in ≥2ndline treatment of HER2-positive MBC with controllable toxicity, and the combination is a new treatment option, especially for patients who cannot use ADCs in 2nd-line treatment.PMID:37916639 | DOI:10.2174/0115680096248592231016065117 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - November 2, 2023 Category: Cancer & Oncology Authors: Fan Wu Mulan Chen Lili Wang Xiufeng Wu Xinhua Chen Yi Hong Chongyin Li Lin Lin Kan Chen Jian Liu Weiwei Huang Nani Li Source Type: research
Crocin Combined With Cisplatin Regulates Proliferation, Apoptosis And Emt Of Gastric Cancer Cells Via The Fgfr3/Mapk/Erk Pathway In Vitro And In Vivo
CONCLUSION: Our results showed that up-regulation of FGFR3 reversed the inhibitory effect of crocin+DDP on the MAPK/ERK signaling pathway. Still, this effect could be counteracted by PD184352, which simultaneously regulated the proliferation, apoptosis, and EMT of AGS cells. In conclusion, crocin, combined with DDP, inhibits proliferation, apoptosis, and EMT of GC through the FRFR3/MAPK/ERK pathway.PMID:37718528 | DOI:10.2174/1568009624666230915111239 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - September 18, 2023 Category: Cancer & Oncology Authors: Yan Li Qi-Jing Guo Rong Chen LingLin Zhao Xianshu Cui Yingfang Deng Yu-Shuang Luo Source Type: research
Crocin Combined With Cisplatin Regulates Proliferation, Apoptosis And Emt Of Gastric Cancer Cells Via The Fgfr3/Mapk/Erk Pathway In Vitro And In Vivo
CONCLUSION: Our results showed that up-regulation of FGFR3 reversed the inhibitory effect of crocin+DDP on the MAPK/ERK signaling pathway. Still, this effect could be counteracted by PD184352, which simultaneously regulated the proliferation, apoptosis, and EMT of AGS cells. In conclusion, crocin, combined with DDP, inhibits proliferation, apoptosis, and EMT of GC through the FRFR3/MAPK/ERK pathway.PMID:37718528 | DOI:10.2174/1568009624666230915111239 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - September 18, 2023 Category: Cancer & Oncology Authors: Yan Li Qi-Jing Guo Rong Chen LingLin Zhao Xianshu Cui Yingfang Deng Yu-Shuang Luo Source Type: research
Crocin Combined With Cisplatin Regulates Proliferation, Apoptosis And Emt Of Gastric Cancer Cells Via The Fgfr3/Mapk/Erk Pathway In Vitro And In Vivo
CONCLUSION: Our results showed that up-regulation of FGFR3 reversed the inhibitory effect of crocin+DDP on the MAPK/ERK signaling pathway. Still, this effect could be counteracted by PD184352, which simultaneously regulated the proliferation, apoptosis, and EMT of AGS cells. In conclusion, crocin, combined with DDP, inhibits proliferation, apoptosis, and EMT of GC through the FRFR3/MAPK/ERK pathway.PMID:37718528 | DOI:10.2174/1568009624666230915111239 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - September 18, 2023 Category: Cancer & Oncology Authors: Yan Li Qi-Jing Guo Rong Chen LingLin Zhao Xianshu Cui Yingfang Deng Yu-Shuang Luo Source Type: research
Crocin Combined With Cisplatin Regulates Proliferation, Apoptosis And Emt Of Gastric Cancer Cells Via The Fgfr3/Mapk/Erk Pathway In Vitro And In Vivo
CONCLUSION: Our results showed that up-regulation of FGFR3 reversed the inhibitory effect of crocin+DDP on the MAPK/ERK signaling pathway. Still, this effect could be counteracted by PD184352, which simultaneously regulated the proliferation, apoptosis, and EMT of AGS cells. In conclusion, crocin, combined with DDP, inhibits proliferation, apoptosis, and EMT of GC through the FRFR3/MAPK/ERK pathway.PMID:37718528 | DOI:10.2174/1568009624666230915111239 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - September 18, 2023 Category: Cancer & Oncology Authors: Yan Li Qi-Jing Guo Rong Chen LingLin Zhao Xianshu Cui Yingfang Deng Yu-Shuang Luo Source Type: research
Crocin Combined With Cisplatin Regulates Proliferation, Apoptosis And Emt Of Gastric Cancer Cells Via The Fgfr3/Mapk/Erk Pathway In Vitro And In Vivo
CONCLUSION: Our results showed that up-regulation of FGFR3 reversed the inhibitory effect of crocin+DDP on the MAPK/ERK signaling pathway. Still, this effect could be counteracted by PD184352, which simultaneously regulated the proliferation, apoptosis, and EMT of AGS cells. In conclusion, crocin, combined with DDP, inhibits proliferation, apoptosis, and EMT of GC through the FRFR3/MAPK/ERK pathway.PMID:37718528 | DOI:10.2174/1568009624666230915111239 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - September 18, 2023 Category: Cancer & Oncology Authors: Yan Li Qi-Jing Guo Rong Chen LingLin Zhao Xianshu Cui Yingfang Deng Yu-Shuang Luo Source Type: research
Crocin Combined With Cisplatin Regulates Proliferation, Apoptosis And Emt Of Gastric Cancer Cells Via The Fgfr3/Mapk/Erk Pathway In Vitro And In Vivo
CONCLUSION: Our results showed that up-regulation of FGFR3 reversed the inhibitory effect of crocin+DDP on the MAPK/ERK signaling pathway. Still, this effect could be counteracted by PD184352, which simultaneously regulated the proliferation, apoptosis, and EMT of AGS cells. In conclusion, crocin, combined with DDP, inhibits proliferation, apoptosis, and EMT of GC through the FRFR3/MAPK/ERK pathway.PMID:37718528 | DOI:10.2174/1568009624666230915111239 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - September 18, 2023 Category: Cancer & Oncology Authors: Yan Li Qi-Jing Guo Rong Chen LingLin Zhao Xianshu Cui Yingfang Deng Yu-Shuang Luo Source Type: research
Crocin Combined With Cisplatin Regulates Proliferation, Apoptosis And Emt Of Gastric Cancer Cells Via The Fgfr3/Mapk/Erk Pathway In Vitro And In Vivo
CONCLUSION: Our results showed that up-regulation of FGFR3 reversed the inhibitory effect of crocin+DDP on the MAPK/ERK signaling pathway. Still, this effect could be counteracted by PD184352, which simultaneously regulated the proliferation, apoptosis, and EMT of AGS cells. In conclusion, crocin, combined with DDP, inhibits proliferation, apoptosis, and EMT of GC through the FRFR3/MAPK/ERK pathway.PMID:37718528 | DOI:10.2174/1568009624666230915111239 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - September 18, 2023 Category: Cancer & Oncology Authors: Yan Li Qi-Jing Guo Rong Chen LingLin Zhao Xianshu Cui Yingfang Deng Yu-Shuang Luo Source Type: research
Crocin Combined With Cisplatin Regulates Proliferation, Apoptosis And Emt Of Gastric Cancer Cells Via The Fgfr3/Mapk/Erk Pathway In Vitro And In Vivo
CONCLUSION: Our results showed that up-regulation of FGFR3 reversed the inhibitory effect of crocin+DDP on the MAPK/ERK signaling pathway. Still, this effect could be counteracted by PD184352, which simultaneously regulated the proliferation, apoptosis, and EMT of AGS cells. In conclusion, crocin, combined with DDP, inhibits proliferation, apoptosis, and EMT of GC through the FRFR3/MAPK/ERK pathway.PMID:37718528 | DOI:10.2174/1568009624666230915111239 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - September 18, 2023 Category: Cancer & Oncology Authors: Yan Li Qi-Jing Guo Rong Chen LingLin Zhao Xianshu Cui Yingfang Deng Yu-Shuang Luo Source Type: research
